文献速递淋巴瘤

SOX11是套细胞淋巴瘤中SAMHD1 ara-CTP酶活性的新型结合伙伴和内源性抑制剂

SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
PubMed 文献 · Blood · 2024-01-18

本研究在套细胞淋巴瘤细胞系中鉴定转录因子SOX11为SAMHD1的新型直接结合伙伴及首个已知内源性抑制剂,SOX11以剂量依赖方式抑制SAMHD1的ara-CTP酶活性并在细胞系和SOX11诱导小鼠模型中增敏阿糖胞苷,在SOX11阴性套细胞淋巴瘤中羟基脲可模拟该抑制。

要点

  • SOX11是SAMHD1的新型直接结合伙伴和首个已知内源性抑制剂。
  • SOX11以剂量依赖方式抑制SAMHD1 ara-CTP酶活性并增敏阿糖胞苷。
  • 在SOX11阴性套细胞淋巴瘤中羟基脲可模拟SOX11介导的ara-CTP酶抑制。

核心结论

  • SOX11是SAMHD1的新型相互作用伙伴及其首个已知内源性抑制剂,可能对临床治疗分层有重要意义。

研究设计与样本

  • 在套细胞淋巴瘤细胞系中进行SOX11免疫共沉淀联合质谱分析,并通过邻位连接试验验证。
  • 体外结合试验检测SAMHD1与SOX11 HMG盒的结合亲和力。
  • 原位交联研究检测SOX11-SAMHD1结合对SAMHD1四聚化的影响。
  • 在细胞系和SOX11诱导的套细胞淋巴瘤小鼠模型中检测SOX11表达对SAMHD1 ara-CTP酶活性和阿糖胞苷敏感性的影响。
  • 在SOX11阴性套细胞淋巴瘤中检测羟基脲对SOX11介导的ara-CTP酶抑制的模拟作用。

主要发现

  • 在套细胞淋巴瘤细胞系中,SOX11免疫共沉淀联合质谱将SAMHD1鉴定为最主要的SOX11相互作用伙伴,并经邻位连接试验验证。
  • 体外,SAMHD1以低微摩尔亲和力与SOX11的HMG盒结合。
  • 原位交联研究表明SOX11-SAMHD1结合导致SAMHD1四聚化减少。
  • SOX11表达以剂量依赖方式抑制SAMHD1 ara-CTP酶活性,导致细胞系和SOX11诱导的套细胞淋巴瘤小鼠模型中阿糖胞苷增敏。
  • 在SOX11阴性套细胞淋巴瘤中,添加近期鉴定的SAMHD1抑制剂羟基脲可模拟SOX11介导的ara-CTP酶抑制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sterile alpha motif and histidine-aspartate (HD) domain-containing protein 1 (SAMHD1) is a deoxynucleoside triphosphate triphosphohydrolase with ara-CTPase activity that confers cytarabine (ara-C) resistance in several hematological malignancies. Targeting SAMHD1's ara-CTPase activity has recently been demonstrated to enhance ara-C efficacy in acute myeloid leukemia. Here, we identify the transcription factor SRY-related HMG-box containing protein 11 (SOX11) as a novel direct binding partner and first known endogenous inhibitor of SAMHD1. SOX11 is aberrantly expressed not only in mantle cell lymphoma (MCL), but also in some Burkitt lymphomas. Coimmunoprecipitation of SOX11 followed by mass spectrometry in MCL cell lines identified SAMHD1 as the top SOX11 interaction partner, which was validated by proximity ligation assay. In vitro, SAMHD1 bound to the HMG box of SOX11 with low-micromolar affinity. In situ crosslinking studies further indicated that SOX11-SAMHD1 binding resulted in a reduced tetramerization of SAMHD1. Functionally, expression of SOX11 inhibited SAMHD1 ara-CTPase activity in a dose-dependent manner resulting in ara-C sensitization in cell lines and in a SOX11-inducible mouse model of MCL. In SOX11-negative MCL, SOX11-mediated ara-CTPase inhibition could be mimicked by adding the recently identified SAMHD1 inhibitor hydroxyurea. Taken together, our results identify SOX11 as a novel SAMHD1 interaction partner and its first known endogenous inhibitor with potentially important implications for clinical therapy stratification.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Abdelrazak Morsy MH, Lilienthal I, Lord M, et al. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma. Blood. 2024. PMID: 38237141. doi:10.1182/blood.2023022241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。